Skip to Main Content


Gilead Sciences Authorize Generic Hepatitis C Treatments for the US Market

By | Leave a Comment

Gilead Sciences, Inc., makers of the Hepatitis C (HCV) drugs Sovaldi, Harvoni, Epclusa, and Vosevi, have announced that they will be releasing authorized generic versions of its two most popular drugs, Harvoni and Epclusa, in the United States. The drugs will be introduced into the U.S. market beginning in January 2019 at a list price of $24,000.

More information can be found here.

Thematic Areas:

Comments are closed.

The views reflected in this expert column are those of the individual authors and do not necessarily represent those of the O’Neill Institute for National and Global Health Law or Georgetown University. This blog is solely informational in nature, and not intended as a substitute for competent legal advice from a licensed and retained attorney in your state or country.

See the full disclaimer and terms of use.